Duration of last depressive episode may influence serum BDNF levels in remitted patients with major depression

Depression and Anxiety

Volumn 29, Issue 9, 2012, Pages 775-779

  Takebayashi, Naoko ^a,b   Maeshima, Hitoshi ^a,b   Baba, Hajime ^a,b   Nakano, Yoshiyuki ^a,b   Satomura, Emi ^a   Kita, Yohei ^a   Namekawa, Yuki ^a,b   Nomoto, Hiroshi ^a   Suzuki, Toshihito ^a,b   Arai, Heii ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b Juntendo University Hospital   (Japan)

Author keywords

BDNF; depression; duration of depressive episode; remission; serum

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE DURATION; FEMALE; HIPPOCAMPUS; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; INPATIENTS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS;

EID: 84865861997     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.21933     Document Type: Article

References (35)

1. Pan W, Banks WA, Fasold MB, et al. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998; 37 (12): 1553-1561.
2. Poduslo JF, Curran GL,. Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res 1996; 36 (2): 280-286.
3. Karege F, Perret G, Bondolfi G, et al. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002; 109 (2): 143-8.
4. Karege F, Bondolfi G, Gervasoni N, et al. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005; 57 (9): 1068-1072.
5. Gonul AS, Akdeniz F, Taneli F, et al. Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci 2005; 255 (6): 381-386.
6. Shimizu E, Hashimoto K, Okamura N, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003; 54 (1): 70-75.
7. Aydemir O, Deveci A, Taneli F,. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29 (2): 261-265.
8. Yoshimura R, Mitoma M, Sugita A, et al. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31 (5): 1034-1037.
9. Gervasoni N, Aubry JM, Bondolfi G, et al. Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology 2005; 51 (4): 234-238.
10. Satomura E, Baba H, Nakano Y, et al. Correlations between brain-derived neurotrophic factor and clinical symptoms in medicated patients with major depression. J Affect Disord 2011; 135: 1-3.
11. Sen S, Duman R, Sanacora G,. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008; 64 (6): 527-532.
12. Molendijk ML, Bus BA, Spinhoven P, et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 2010; 16 (11): 1088-1095.
13. Laske C, Banschbach S, Stransky E, et al. Exercise-induced normalization of decreased BDNF serum concentration in elderly women with remitted major depression. Int J Neuropsychopharmacol 2010; 13 (5): 595-602.
14. Hamilton MA,. Rating scale for depression. J Neurol Neurosurg Psychiatr 1960; 23: 56-62.
15. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48 (9): 851-855.
16. Inagaki A, Inaba T,. Dose equivalence of psychotropic drugs. part X VIII dose equivalence of psychotropic drugs: 2006-version. Jpn J Clin Psychopharmacol 2006; 9 (7): 1443-1447.
17. Matsuoka K, Uno M, Kasai K, et al. Estimation of premorbid IQ in individuals with Alzheimer's disease using Japanese ideographic script (Kanji) compound words: Japanese version of National Adult Reading Test. Psychiatry Clin Neurosci 2006; 60 (3): 332-339.
18. Minelli A, Zanardini R, Bonvicini C, et al. BDNF serum levels, but not BDNF Val66Met genotype, are correlated with personality traits in healthy subjects. Eur Arch Psychiatry Clin Neurosci 2011; 261 (5): 323-329.
19. Lommatzsch M, Zingler D, Schuhbaeck K, et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 2005; 26 (1): 115-123.
20. Campbell S, Marriott M, Nahmias C, MacQueen GM,. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry 2004; 161 (4): 598-607.
21. Pantel J, Schroder J, Essig M, et al. Quantitative magnetic resonance imaging in geriatric depression and primary degenerative dementia. J Affect Disord 1997; 42 (1): 69-83.
22. Zubenko GS, Sullivan P, Nelson JP, et al. Brain imaging abnormalities in mental disorders of late life. Arch Neurol 1990; 47 (10): 1107-1111.
23. Volz HP, Rzanny R, Rossger G, et al. 31Phosphorus magnetic resonance spectroscopy of the dorsolateral prefrontal region in schizophrenics-a study including 50 patients and 36 controls. Biol Psychiatry 1998; 44 (6): 399-404.
24. Sheline YI, Wang PW, Gado MH, et al. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 1996; 93 (9): 3908-3913.
25. O'Brien JT, Lloyd A, McKeith I, et al. A longitudinal study of hippocampal volume, cortisol levels, and cognition in older depressed subjects. Am J Psychiatry 2004; 161 (11): 2081-2090.
26. Axelson DA, Doraiswamy PM, McDonald WM, et al. Hypercortisolemia and hippocampal changes in depression. Psychiatry Res 1993; 47 (2): 163-173.
27. Coffey CE, Wilkinson WE, Weiner RD, et al. The dexamethasone suppression test and quantitative cerebral anatomy in depression. Biol Psychiatry 1993; 33 (6): 442-449.
28. Czeh B, Michaelis T, Watanabe T, et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci USA 2001; 98 (22): 12796-12801.
29. Magarinos AM, Deslandes A, McEwen BS,. Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Eur J Pharmacol 1999; 371 (2-3): 113-122.
30. Malberg JE, Eisch AJ, Nestler EJ, Duman RS,. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20 (24): 9104-9110.
31. Rajkowska G,. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 2000; 48 (8): 766-777.
32. McEwen BS,. Stress and hippocampal plasticity. Annu Rev Neurosci 1999; 22: 105-122.
33. Bueller JA, Aftab M, Sen S, et al. BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects. Biol Psychiatry 2006; 59 (9): 812-815.
34. Erickson KI, Prakash RS, Voss MW, et al. Brain-derived neurotrophic factor is associated with age-related decline in hippocampal volume. J Neurosci 2010; 30 (15): 5368-5375.
35. Duman RS, Monteggia LM,. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59 (12): 1116-1127.